REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
1.610 USD   -5.29%
08/04Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call
PR
07/15REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10

06/29/2022 EDT

A split is applied today to Regulus Therapeutics Inc.'s stock price.



© Factset 2022
All news about REGULUS THERAPEUTICS INC.
08/04Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast..
PR
07/15REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
06/28Wall Street Set to Open Higher
MT
06/28Top Premarket Decliners
MT
06/27REGULUS THERAPEUTICS INC. : Material Modification to Rights of Security Holders, Financial..
AQ
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
PR
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
CI
06/21Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429
DJ
06/13REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -28,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,93x
Yield 2022 -
Capitalization 23,5 M 23,5 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 11,3x
Nbr of Employees 25
Free-Float 9,47%
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,61 $
Average target price 14,00 $
Spread / Average Target 770%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-48.89%24
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093